Why the study?
Heart failure with reduced ejection fraction produces substantial morbidity, mortality, and health care costs, motivating an evaluation of the cost-effectiveness of adding dapagliflozin to guideline-directed medical therapy in patients with or without diabetes.
Is dapagliflozin added to guideline-directed medical therapy cost-effective for the treatment of heart failure with reduced ejection fraction in US adults?
Is dapagliflozin added to guideline-directed medical therapy cost-effective for the treatment of heart failure with reduced ejection fraction in US adults?
Adding dapagliflozin to guideline-directed medical therapy for HFrEF is projected to be cost-effective at current US prices, with an ICER of $68,300 per QALY gained.
Answers are grounded in this paper and cite their sources.
Dapagliflozin addition to GDMT may be cost-effective in HFrEF; leaves open real-world adoption pending pricing and implementation data.
Importance: Heart failure with reduced ejection fraction produces substantial morbidity, mortality, and health care costs. Dapagliflozin is the first sodium-glucose cotransporter 2 inhibitor approved for the treatment of heart failure with reduced ejection fraction. Objective: To examine the cost-effectiveness of adding dapagliflozin to guideline-directed medical therapy for heart failure with reduced ejection fraction in patients with or without diabetes. Design, Setting, and Participants: This economic evaluation developed and used a Markov cohort model that compared dapagliflozin and guideline-directed medical therapy with guideline-directed medical therapy alone in a hypothetical cohort of US adults with similar clinical characteristics as participants of the Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF) trial. Dapagliflozin was assumed to cost $4192 annually. Nonparametric modeling was used to estimate long-term survival. Deterministic and probabilistic sensitivity analyses examined the impact of parameter uncertainty. Data were analyzed between September 2019 and January 2021. Main Outcomes and Measures: Lifetime incremental cost-effectiveness ratio in 2020 US dollars per quality-adjusted life-year (QALY) gained. Results: The simulated cohort had a starting age of 66 years, and 41.8% had diabetes at baseline. Median (interquartile range) survival in the guideline-directed medical therapy arm was 6.8 (3.5-11.3) years. Dapagliflozin was projected to add 0.63 (95% uncertainty interval [UI], 0.25-1.15) QALYs at an incremental lifetime cost of $42 800 (95% UI, $37 100-$50 300), for an incremental cost-effectiveness ratio of $68 300 per QALY gained (95% UI, $54 600-$117 600 per QALY gained; cost-effective in 94% of probabilistic simulations at a threshold of $100 000 per QALY gained). Findings were similar in individuals with or without diabetes but were sensitive to drug cost. Conclusions and Relevance: In this study, adding dapagliflozin to guideline-directed medical therapy was projected to improve long-term clinical outcomes in patients with heart failure with reduced ejection fraction and be cost-effective at current US prices. Scalable strategies for improving uptake of dapagliflozin may improve long-term outcomes in patients with heart failure with reduced ejection fraction.
No takes yet. Share an insight, caveat, or question.
Isaza et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: